News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
66 Results
Type
Company Profile (1)
Press Release (65)
Section
Business (23)
Deals (2)
Drug Development (4)
Job Trends (12)
News (29)
Tag
Alliances (2)
Best Places to Work (13)
Biotechnology (1)
Clinical research (8)
Data (2)
Duchenne muscular dystrophy (3)
Earnings (15)
Events (17)
Executive appointments (1)
IPO (3)
NextGen: Class of 2025 (1)
People (12)
Phase I (8)
Phase II (3)
Regulatory (1)
Date
Last 30 days (3)
Last 365 days (17)
2025 (8)
2024 (15)
2023 (17)
2022 (13)
2021 (6)
2020 (3)
2019 (3)
2018 (1)
Location
Massachusetts (15)
United States (15)
66 Results for "entradatx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to six newly-hired non-executive employees
June 2, 2025
·
1 min read
Press Releases
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 3, 2025
·
4 min read
Press Releases
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
May 28, 2025
·
7 min read
Press Releases
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
·
1 min read
Press Releases
Entrada Therapeutics Reports First Quarter 2025 Financial Results
May 9, 2025
·
10 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
March 25, 2025
·
7 min read
Press Releases
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
February 24, 2025
·
7 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
February 3, 2025
·
8 min read
Press Releases
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
·
9 min read
Press Releases
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
September 24, 2024
·
3 min read
1 of 7
Next
